Synthaverse Reports Third Quarter 2024 Earnings

Simply Wall St

November 22, 2024

Synthaverse (WSE:SVE) Third Quarter 2024 Results

Key Financial Results

Revenue: zł13.4m (up 65% from 3Q 2023).
Net loss: zł444.0k (loss narrowed by 82% from 3Q 2023).

earnings-and-revenue-history — WSE:SVE Earnings and Revenue History November 22nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Synthaverse's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Synthaverse is showing 3 warning signs in our investment analysis and 2 of those can't be ignored...

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About WSE:SVE

Synthaverse

A pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally.

See The Free Research Report

Acceptable track record low.

See The Free Research Report